Impact of Lewy Body Co-Pathology on Clinical and Imaging Characteristics in Amnestic Patients

Overview

Lewy body (LB) co-pathology in Alzheimer’s disease (AD) patients is associated with more severe hypometabolism and faster cognitive decline but does not alter the typical AD regional hypometabolic pattern or memory-predominant cognitive profile. In contrast, patients with relatively pure LB pathology exhibit a distinct posterior-occipital hypometabolism pattern and a dysexecutive/visuospatial cognitive profile, highlighting different clinical phenotypes depending on AD co-morbidity.

Background

Alzheimer’s disease (AD) is characterized by amyloid-β plaques and tau tangles leading to temporo-parietal neurodegeneration and memory deficits. Lewy body (LB) pathology, composed of misfolded α-synuclein, typically presents with a dysexecutive cognitive profile and neuropsychiatric symptoms such as hallucinations, along with a posterior-occipital hypometabolism pattern on FDG-PET imaging. LB pathology is found as a co-pathology in approximately 50% of AD patients and may influence clinical trajectories and neurodegeneration patterns in amnestic patients, but its precise impact remains unclear.

Data Highlights

Key Findings

• AD patients with LB co-pathology (AD+LB+) show more severe hypometabolism and faster cognitive decline than those without LB (AD+LB−), but both share similar temporo-parietal hypometabolic patterns and memory-predominant cognitive profiles.
• Patients with relatively pure LB pathology (AD−LB+) exhibit a distinct posterior-occipital hypometabolism pattern and a dysexecutive/visuospatial cognitive profile, differing from typical AD presentations.
• APOE4 genotype frequency is similar between AD+LB+ and AD+LB− groups (~72-75%) but significantly lower in AD−LB+ patients (28%).
• Risk of developing hallucinations is comparable across AD+LB+, AD+LB−, and AD−LB+ groups overall, but patients with LB-like posterior-occipital hypometabolism have a significantly higher hallucination risk (hazard ratio 2.58).
• LB co-pathology does not alter the regional hypometabolic pattern characteristic of AD but is associated with more severe neurodegeneration and clinical decline.
• The presence of LB pathology may lead to different clinical phenotypes depending on AD co-morbidity, impacting diagnosis and prognosis in amnestic syndromes.

Clinical Implications

Recognition of LB co-pathology in AD patients is important as it is linked to faster cognitive decline and more severe hypometabolism, although it does not change the typical AD imaging pattern. Identifying patients with pure LB pathology is critical due to their distinct cognitive profiles and imaging features, which may necessitate different management strategies. Clinicians should consider these differences for accurate diagnosis, prognosis, and tailored therapeutic approaches in amnestic patients.

Conclusion

Lewy body co-pathology in amnestic patients influences clinical severity and progression differently depending on the presence of AD pathology, underscoring the need for biomarker-informed diagnosis to guide prognosis and treatment. Distinct imaging and cognitive profiles associated with LB pathology highlight its critical role in the heterogeneity of amnestic syndromes.

References

1. Original Article -- Impact of Lewy Body Co-Pathology on Clinical and Imaging Characteristics in Amnestic Patients